Tuspark Becomes Latest Partner of One Nucleus

Cambridge UK: 17 July 2019

Tuspark has become the latest Partner to join forces with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs both of the Partner and the interests of One Nucleus members.

Kevin Lin, President of Tuspark UK commented 'Tony and I met at *ON Helix* last year, after in-depth discussion, we reached a consensus of promoting innovation network and clusters not only in Cambridge but globally. We're delighted to be a partner of One Nucleus, which is playing a leading role in European life science and healthcare network, and we expect to meet more innovations by connecting global networks of both parties.'

Tony Jones, CEO of One Nucleus expands further 'We are delighted to welcome Tuspark to the One Nucleus Partner Programme. Their expertise in supporting innovation with facilities and investment are great asset for the life science community. Their engagement in Cambridge, both the substantial investment in Cambridge Science Park and equity investment in local companies are great early examples of their commitment and approach. We are looking forward to developing this partnership to benefit more of our members and the wider Cambridge biotech scene'.

ENDS

About Tuspark

TusPark is a leading global ecosystem in technology and service. TusPark manages over 300 incubators, science parks, and science cities worldwide, and invests in 7 sectors including life sciences. It has incubated over 6,000 enterprises and 36 of these are successful listed. Tuspark has assets under management of more than £20 billion and over 800 portfolios including 9 publicly listed companies.

In the UK, TusPark has launched two science parks - TusPark Cambridge and TusPark Newcastle. Tuspark Cambridge is a landmark £200 million joint venture with Trinity College, University of Cambridge, which includes 350,000 sq. ft of office/lab space that is developed over five new buildings, including the aforementioned state-of-the-art Bio-Innovation Centre. Together with a few other facilities to be built in the Cambridge Science Park, the Bio-Innovation Centre is expected to provide space, business support and global opportunities for life science start-ups and scale-ups.

In addition to the science parks, TusPark UK has also made equity investments into a few Cambridge life science start-ups as well as the Cambridge Innovation Capital. It partnered with Innovate UK on helping British start-ups soft-land and accelerate in China and will continue to work with UK and Chinese governments, businesses, associations, universities, and institutions on cross-border collaborations.

For further information, please visit [www.tuspark.co.uk,](www.tuspark.co.uk) or follow TusPark UK on Twitter [@TusparkUK](https://twitter.com/TusparkUK) and LinkedIn [@TusPark UK](https://linkedin.com)

About One Nucleus

Established in 1997, One Nucleus is an award winning not-for-profit Life Sciences & Healthcare membership organisation centred on the Greater London-Cambridge-East of England corridor. Headquartered in Cambridge, at the heart of Europe's largest Life Sciences & Healthcare cluster, we support those institutions, companies and individuals undertaking activity in or with the above region.

Through providing the local, UK-wide and international connectivity, One Nucleus seeks to enable our members to maximise their performance. This support helping them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D have always been impactful in driving social and economic progress. In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development. Attracting and enabling the best people to engage with is at

the heart of the One Nucleus team ethos and what we continually strive to deliver.

For further information, please contact:

Tony Jones, CEO
Email: Tony@onenucleus.com
Tel: +44 (0)1223 896463
Web: www.onenucleus.com